Igor A.
- Country
- Croatia
- Department
- Zavod za hematologiju
Research Overview
- Efficacy and Safety Comparison of Obinutuzumab-Venetoclax vs. Obinutuzumab-Chlorambucil in Untreated CLL with Comorbidities
- Phase 3 Randomized Study of Pirtobrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in BTK Inhibitor-Pretreated CLL/SLL Patients
- Phase II Evaluation of Safety and Efficacy of MB-CART2019.1 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Following Lymphodepletion Regimen
Data & Insights
Has run more than one trial at 80 of 258 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating advanced blood cancers, with particular emphasis on lymphoid malignancies.
- Diffuse Large B Cell Lymphoma (DLBCL)
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
The investigator has experience in managing both newly diagnosed and relapsed/refractory cases.
Innovative Therapies
Focus on pioneering therapeutic approaches including cellular therapy and novel targeted treatments.
- CAR-T Cell Therapy
- BTK Inhibition
- Targeted Molecular Therapies
The investigator works with emerging therapeutic modalities for blood cancers resistant to conventional treatments.
Combination Approaches
Expertise in developing combination treatment strategies for hematologic conditions.
- Antibody-Based Therapies
- Novel Drug Combinations
- Personalized Treatment Approaches
The investigator explores therapeutic combinations tailored for patients with coexisting medical conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.